Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Anemia 55Neoplasms 25Multiple Myeloma 10Leukemia 10Neoplasms, Plasma Cell 8Lymphoma 8Lymphoma, Non-Hodgkin 6Leukemia, Lymphocytic, Chronic, B-Cell 6Breast Neoplasms 6Precancerous Conditions 5Lymphoma, Follicular 5Hodgkin Disease 5Waldenstrom Macroglobulinemia 4Lymphoproliferative Disorders 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, B-Cell, Marginal Zone 4Sezary Syndrome 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Mycosis Fungoides 3Monoclonal Gammopathy of Undetermined Significance 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Large-Cell, Anaplastic 3Leukemia, Prolymphocytic 3Leukemia, Large Granular Lymphocytic 3Immunoglobulin Light-chain Amyloidosis 3Immunoblastic Lymphadenopathy 3Fatigue 3

Interventions

fludarabine phosphate 2fludarabine 2Melphalan 2Bone Marrow Transplantation 2thymoglobulin 1pegylated granulocyte colony-stimulating factor 1Whole-Body Irradiation 1Tacrolimus 1RFT5-SMPT-dgA immunotoxin 1Peripheral Blood Stem Cell Transplantation 1Mycophenolic Acid 1Epoetin Alfa 1Cyclophosphamide 1Busulfan 1Biopsy 1Ascorbic Acid 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Lymphoid × Epoetin Alfa × Classical hematology × Clear all
NCT00270049 2011-05-18

Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 2 Completed
195 enrolled
Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Leukemia, Leukemia, Lymphoid, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡